In a groundbreaking move that could reshape the landscape of women’s health, the long-standing term polycystic ovary syndrome (PCOS) has been officially transformed into polyendocrine metabolic ovarian syndrome (PMOS). This change, announced on May 12 in *The Lancet*, marks the culmination of over a decade of advocacy and research, aiming to elevate awareness and understanding of a condition that affects approximately one in eight women globally.
The Shift in Terminology: Why It Matters
The previous designation of PCOS has long been considered misleading. Contrary to its name, the condition does not primarily feature abnormal ovarian cysts. Instead, it is characterised by disrupted hormone levels leading to the development of fluid-filled sacs known as follicles, which can interfere with normal ovarian function. This misunderstanding has contributed to a significant number of women remaining undiagnosed and untreated—an estimated 70% of those affected globally have never received a formal diagnosis.
“The old name has significantly hampered awareness and education, leading to a lack of research funding and attention,” noted a spokesperson from Monash University, a leading voice in this initiative. The new nomenclature, PMOS, better encapsulates the diverse metabolic and hormonal disturbances that this syndrome entails, including its associations with diabetes, heart disease, infertility, and mental health issues.
Understanding PMOS: A Multifaceted Condition
PMOS is not merely a reproductive disorder but a complex, chronic condition with far-reaching implications for women’s overall health. Symptoms often extend beyond the reproductive system, encompassing a range of metabolic challenges, including insulin resistance and increased risk of Type 2 diabetes. Depression, anxiety, and related eating disorders are also prevalent among those affected, complicating their health further.
Robyn Vettese, Chair of the PMOS Patient Advisory Council, expressed optimism regarding the name change. “By acknowledging the multifaceted nature of PMOS, we hope to foster a deeper understanding among healthcare providers and ensure that all patients receive the comprehensive care they deserve,” she stated.
The Process of Change: A Collective Effort
The journey to rebranding PCOS to PMOS is heralded as one of the largest global engagement efforts in health history. In 2025, a pivotal survey revealed that 85.6% of patients and 76.1% of healthcare professionals supported the name change. This overwhelming consensus was built on the participation of over 22,000 individuals—including health professionals and those living with PMOS—alongside the collaboration of 56 leading health organisations.
Professor Helena Teede, who led the name change initiative, emphasized the importance of this collective effort. “This change reflects a deeper understanding of the condition and highlights the necessity of integrating patients’ voices into healthcare discussions,” she remarked.
A Call to Action for Future Research and Support
Looking forward, the renaming of PCOS to PMOS serves as a clarion call for enhanced education and research into the condition. Experts like Dr. Jamie Benham are committed to raising awareness about the implications of this change, pushing for increased funding for research, and advocating for a holistic approach to treatment.
The recent *McKinsey Health Institute* report underscored the urgent need to close the health gap for women, indicating that without concerted efforts, many will continue to suffer from inadequate care. With the new name firmly established, there is hope that PMOS will receive the attention and resources necessary to improve diagnosis, management, and support for those affected.
Why it Matters
The renaming of PCOS to PMOS represents more than just a shift in terminology; it is a significant step towards transforming women’s healthcare. By accurately capturing the complexities of this condition, there is a renewed potential for increased awareness, funding, and ultimately, better health outcomes for millions of women worldwide. As the medical community rallies around this change, it is imperative that the focus remains on empowering those affected by PMOS, ensuring they receive the comprehensive care and understanding they deserve. This landmark decision not only aims to enhance the quality of life for women but also sets a precedent for future health initiatives centred on patient experience and needs.
